TNFSF10 and coronary artery disorder: Similar results were also found in previous clinical studies: plasma levels of TRAIL were lower for patients with coronary artery disease and myocardial infraction than controls, and the plasma level of TRAIL decreased with increasing number of coronary arteries with atherosclerosis [7,10].